Dry Age-Related Macular Degeneration (Dry AMD) market is expected to reach USD 10 billion by 2034

Dry age-related macular degeneration (Dry AMD) is a progressive eye disorder that damages the macula, the central region of the retina responsible for sharp vision. It is the most common form of AMD, accounting for nearly 85-90% of all cases, though it progresses more slowly than wet AMD. Dry AMD typically develops with age and is characterized by the accumulation of drusen (yellow deposits) beneath the retina, leading to gradual central vision loss.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72227

With aging populations worldwide and longer life expectancies, Dry AMD is becoming a major cause of irreversible vision impairment and blindness in older adults. The market is expanding rapidly as healthcare systems focus on preventive ophthalmology, research into new therapies, and advanced diagnostic technologies. Although no definitive cure exists, promising therapeutic pipelines, lifestyle management strategies, and technological innovations are driving optimism for patients and stakeholders alike.

Market Overview
According to Exactitude Consultancy, the global Dry Age-Related Macular Degeneration Market was valued at USD 5.2 billion in 2024 and is projected to reach USD 10 billion by 2034, growing at a CAGR of 7.2% between 2025 and 2034.

Key Highlights
• Largest form of AMD: Dry AMD dominates the AMD patient pool and poses a significant unmet need.
• Drivers: Rising aging population, advancements in diagnostic imaging (OCT, AI-based retinal scans), and growing clinical research on novel therapies.
• Challenges: Lack of curative treatments, high costs of emerging therapies, and patient adherence issues.
• Leading players: Apellis Pharmaceuticals, Iveric Bio (Astellas), Roche, Novartis, and Regeneron are pioneering innovation in Dry AMD treatment.

Segmentation Analysis
The Dry AMD market can be segmented by disease stage, treatment type, end use, and region.
By Disease Stage
• Early-stage Dry AMD
• Intermediate Dry AMD
• Advanced (geographic atrophy)

By Treatment Type
• Nutritional supplements (AREDS formulations, antioxidants, vitamins)
• Emerging biologics and gene therapies
• Stem cell and regenerative medicine
• Assistive devices and digital solutions

By End Use
• Hospitals
• Specialty eye clinics
• Ambulatory surgical centers
• Homecare settings

Segmentation Summary
Nutritional supplements currently dominate, as they are widely prescribed to slow progression in early and intermediate stages. However, emerging biologics and gene therapies are expected to be the fastest-growing segment, particularly for advanced Dry AMD and geographic atrophy. Assistive devices and digital health tools remain critical for improving quality of life in advanced cases.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72227/dry-age-related-macular-degeneration-market

Regional Analysis
North America
• Largest market due to high prevalence of AMD, advanced ophthalmology infrastructure, and early adoption of new therapies.
• The U.S. leads in both therapeutic innovation and clinical trials, with strong presence of biotech companies.
Europe
• Strong adoption in Germany, the U.K., and France, supported by national healthcare systems and aging populations.
• EU-backed research initiatives in ophthalmology are contributing to innovation.
Asia-Pacific
• Expected to record the fastest CAGR through 2034.
• Rising elderly populations in China and Japan, combined with increasing healthcare investments, are expanding the patient pool.
• India is emerging as a cost-sensitive but high-potential market.
Middle East & Africa
• Moderate growth, with GCC countries leading adoption of advanced ophthalmic care.
• In Africa, access to eye care remains limited, though NGOs are expanding awareness campaigns.
Latin America
• Brazil and Mexico are key markets, driven by expanding healthcare infrastructure and greater awareness of AMD.
Regional Summary
While North America dominates the market today, Asia-Pacific will grow fastest due to demographic changes, healthcare modernization, and growing investments in ophthalmology.

Market Dynamics
Key Growth Drivers
1. Aging demographics - A rapidly growing elderly population increases the prevalence of Dry AMD worldwide.
2. Innovation in therapies - Advances in biologics, gene therapies, and regenerative medicine are reshaping treatment pathways.
3. Diagnostic advancements - AI-assisted imaging and optical coherence tomography (OCT) enable earlier detection.
4. Public awareness initiatives - Screening programs and educational campaigns promote early diagnosis and treatment adherence.

Key Challenges
1. Lack of curative options - Current treatments mainly focus on slowing progression rather than reversing damage.
2. High treatment costs - Emerging biologics and cell therapies may limit access in developing regions.
3. Compliance issues - Patients often struggle with adherence to long-term nutritional and therapeutic regimens.

Latest Trends
• Complement inhibitors: Targeting complement pathways to reduce progression in geographic atrophy.
• Gene therapy and stem cell approaches: Offering hope for long-term or one-time treatment solutions.
• Digital health and AI tools: Supporting remote monitoring and personalized disease management.
• Combination strategies: Integrating lifestyle management with pharmacological interventions.

Explore Full Report here: https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72227

Competitor Analysis
Major Players in the Dry AMD Market
• Apellis Pharmaceuticals, Inc.
• Iveric Bio (Astellas Pharma Inc.)
• Roche Holding AG
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Allergan (AbbVie Inc.)
• Gyroscope Therapeutics Ltd.
• Kodiak Sciences Inc.
• Lineage Cell Therapeutics Inc.
• Genentech (Roche subsidiary)

Competitive Dynamics
Apellis and Iveric Bio are leading the charge with novel complement inhibitors and therapies for geographic atrophy. Roche, Novartis, and Regeneron dominate with strong ophthalmology portfolios and R&D pipelines. Smaller biotech firms such as Lineage and Gyroscope are advancing stem cell and gene therapy approaches. Partnerships, licensing agreements, and expanded clinical trials are central to competition in this space.

Conclusion
The Dry Age-Related Macular Degeneration Market is set for strong growth, with the market size expected to nearly double from USD 5.2 billion in 2024 to USD 10 billion by 2034, at a CAGR of 7.2%.

Key opportunities include:
• Expanding adoption of biologics and complement inhibitors for geographic atrophy.
• Scaling gene therapy and regenerative medicine approaches.
• Leveraging AI-driven diagnostics for earlier detection and personalized care.
• Strengthening access to treatment in emerging economies.

Although challenges such as high treatment costs and lack of curative options remain, innovation in therapy development and diagnostic technologies promises a transformative decade for Dry AMD care.

In conclusion, the Dry AMD market is evolving rapidly, offering new hope for millions of patients at risk of vision loss and creating significant opportunities for innovators and investors worldwide.

This report is also available in the following languages : Japanese (ドライ型加齢黄斑変性市場), Korean (건성 연령관련 황반변성 시장), Chinese (干性老年性黄斑变性市场), French (Marché de la dégénérescence maculaire sèche liée à l'âge), German (Markt für trockene altersbedingte Makuladegeneration), and Italian (Mercato della degenerazione maculare secca legata all'età), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72227/dry-age-related-macular-degeneration-market#request-a-sample

Our More Reports:

HER2-Negative Breast Cancer Epidemiology Market
https://exactitudeconsultancy.com/reports/73664/her2-negative-breast-cancer-epidemiology-market

New Drug Approvals and Their Contract Manufacture Market
https://exactitudeconsultancy.com/reports/73665/new-drug-approvals-and-their-contract-manufacture-market

Blockbuster Drugs on Patent Cliffs Market
https://exactitudeconsultancy.com/reports/73666/blockbuster-drugs-on-patent-cliffs-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.